PE20181354A1 - Mutantes de proteina f de rsv - Google Patents
Mutantes de proteina f de rsvInfo
- Publication number
- PE20181354A1 PE20181354A1 PE2018001128A PE2018001128A PE20181354A1 PE 20181354 A1 PE20181354 A1 PE 20181354A1 PE 2018001128 A PE2018001128 A PE 2018001128A PE 2018001128 A PE2018001128 A PE 2018001128A PE 20181354 A1 PE20181354 A1 PE 20181354A1
- Authority
- PE
- Peru
- Prior art keywords
- mutation
- combination
- electrostatic
- protein
- mutant
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 abstract 14
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 3
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 3
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se refiere a un mutante de proteina F de virus sincicial respiratorio (RSV) de tipo silvestre, cuyo mutante comprende un polipeptido F1 y un polipeptido F2, en donde el mutante comprende al menos una mutacion de aminoacidos de la proteina F de RSV de tipo silvestre, y en donde la mutacion de aminoacidos se selecciona del grupo consistente de una mutacion de enlace disulfuro, una mutacion de carga de cavidad, una mutacion electrostatica, una combinacion de al menos una mutacion de disulfuro disenada y al menos una mutacion de carga de cavidad, una combinacion de al menos una mutacion de disulfuro disenada y al menos una mutacion electrostatica, una combinacion de al menos una mutacion de carga de cavidad y al menos una mutacion electrostatica, y una combinacion de al menos una mutacion de disulfuro disenada, al menos una mutacion de carga de cavidad y al menos una mutacion electrostatica. Tambien se refiere a una vacuna y un metodo. Dicho mutante de proteina reduce la infeccion por RSV
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387270P | 2015-12-23 | 2015-12-23 | |
US201662421184P | 2016-11-11 | 2016-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181354A1 true PE20181354A1 (es) | 2018-08-22 |
Family
ID=57590746
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001148A PE20240817A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
PE2018001128A PE20181354A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
PE2023001147A PE20232039A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001148A PE20240817A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001147A PE20232039A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
Country Status (18)
Country | Link |
---|---|
US (5) | US9950058B2 (es) |
EP (1) | EP3393512A1 (es) |
JP (4) | JP6817307B2 (es) |
KR (3) | KR20230035429A (es) |
CN (1) | CN108738312A (es) |
AU (4) | AU2016379097C1 (es) |
BR (1) | BR112018010805A2 (es) |
CA (2) | CA2952131C (es) |
CO (1) | CO2018006301A2 (es) |
IL (2) | IL260203B1 (es) |
MX (2) | MX2018007622A (es) |
PE (3) | PE20240817A1 (es) |
PH (1) | PH12018501355A1 (es) |
RU (1) | RU2723039C2 (es) |
SA (2) | SA522433260B1 (es) |
SG (2) | SG10202001389PA (es) |
TW (4) | TWI707866B (es) |
WO (1) | WO2017109629A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
MX2019011869A (es) | 2017-04-04 | 2020-01-09 | Univ Washington | Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. |
KR20200035115A (ko) | 2017-08-07 | 2020-04-01 | 칼더 바이오사이언시스 인코포레이티드 | 입체형태적으로 안정화된 rsv 융합전 f 단백질 |
WO2019147749A2 (en) * | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
KR20200138234A (ko) | 2018-02-28 | 2020-12-09 | 유니버시티 오브 워싱톤 | 자기 조립 나노구조 백신 |
BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
KR20210091749A (ko) * | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN110054668B (zh) * | 2019-04-25 | 2021-09-10 | 北京交通大学 | 一种呼吸道合胞病毒融合前f蛋白及其应用 |
US20230201334A1 (en) | 2019-07-24 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
WO2021046207A1 (en) | 2019-09-04 | 2021-03-11 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
EP4083212A4 (en) | 2019-12-23 | 2024-03-27 | Mitsubishi Tanabe Pharma Corporation | MUTANT RSV-F PROTEIN AND ITS USE |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
CN112899214B (zh) * | 2020-07-07 | 2023-08-04 | 湖南师范大学 | 废弃鱼鳞在制备各向异性基底中的应用 |
JP2022023813A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたrsvタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
JP2022023814A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のrsvタンパク質の精製方法 |
CN112226444B (zh) * | 2020-08-25 | 2022-11-04 | 北京交通大学 | 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品 |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN114685676B (zh) * | 2020-12-28 | 2024-02-13 | 兰州生物制品研究所有限责任公司 | 一种重组蛋白及其表达方法、纯化方法及用途 |
KR20230147156A (ko) * | 2021-02-19 | 2023-10-20 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 rsv fb 항원 |
EP4333879A1 (en) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
CN117715923A (zh) * | 2022-04-29 | 2024-03-15 | 北京新合睿恩生物医疗科技有限公司 | Rsv f蛋白突变体及其应用 |
WO2024041772A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
CN116003536A (zh) * | 2022-09-23 | 2023-04-25 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN117986382A (zh) * | 2022-11-04 | 2024-05-07 | 北京康乐卫士生物技术股份有限公司 | 针对rsv的重组亚单位疫苗及其应用 |
CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
US20240252612A1 (en) | 2022-12-11 | 2024-08-01 | Pfizer Inc. | Immunogenic compositions and uses thereof |
US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
CN117487823A (zh) * | 2023-09-28 | 2024-02-02 | 怡道生物科技(苏州)有限公司 | 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用 |
CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304279B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117567652B (zh) * | 2024-01-19 | 2024-05-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原 |
CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
CN117645655B (zh) * | 2024-01-26 | 2024-05-24 | 普大生物科技(泰州)有限公司 | 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法 |
CN117777251B (zh) * | 2024-02-27 | 2024-06-04 | 普大生物科技(泰州)有限公司 | 一种rsv纳米颗粒疫苗及其制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
JP2010522540A (ja) | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
WO2008154456A2 (en) | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
EP4219566A3 (en) * | 2007-12-24 | 2023-09-06 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
BRPI0915960A2 (pt) | 2008-07-18 | 2019-09-24 | Id Biomedical Corp | antígenos de polipeptídeos do vírus sincicial respiratório qimérico |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
WO2010077717A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
US9492531B2 (en) * | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
EA201270062A1 (ru) * | 2009-06-24 | 2013-02-28 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Вакцина |
ES2918381T3 (es) | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
EP2486053B1 (en) | 2009-10-06 | 2017-01-18 | Medimmune Limited | Rsv-specific binding molecule |
WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
DK2667892T3 (da) | 2011-01-26 | 2019-05-13 | Glaxosmithkline Biologicals Sa | RSV-vaccineringsprogram |
JP2014519819A (ja) * | 2011-05-13 | 2014-08-21 | ノバルティス アーゲー | 融合前rsvf抗原 |
ES2395677B1 (es) | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
CA2849471A1 (en) | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
BR112014023196B1 (pt) | 2012-03-22 | 2021-09-08 | Janssen Vaccines & Prevention B.V. | Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado |
EP2922570A1 (en) | 2012-11-20 | 2015-09-30 | GlaxoSmithKline Biologicals SA | Rsv f prefusion trimers |
CA2902877A1 (en) * | 2013-03-13 | 2014-10-02 | Jeffrey Boyington | Prefusion rsv f proteins and their use |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
DK2988780T3 (en) | 2013-04-25 | 2019-04-08 | Janssen Vaccines & Prevention Bv | STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES |
EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
US20150166610A1 (en) * | 2013-10-14 | 2015-06-18 | Glaxosmithkline Biologicals, S.A. | Recombinant rsv antigens |
EP2974739A1 (en) * | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
EP3344290A4 (en) * | 2015-08-31 | 2019-02-27 | Technovax, Inc. | VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV) |
US10496141B2 (en) | 2016-03-17 | 2019-12-03 | Qualcomm Incorporated | System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture |
-
2016
- 2016-12-09 RU RU2018122823A patent/RU2723039C2/ru active
- 2016-12-09 KR KR1020237006668A patent/KR20230035429A/ko not_active Application Discontinuation
- 2016-12-09 WO PCT/IB2016/057502 patent/WO2017109629A1/en active Application Filing
- 2016-12-09 AU AU2016379097A patent/AU2016379097C1/en active Active
- 2016-12-09 KR KR1020187017606A patent/KR102136678B1/ko active IP Right Grant
- 2016-12-09 MX MX2018007622A patent/MX2018007622A/es unknown
- 2016-12-09 SG SG10202001389PA patent/SG10202001389PA/en unknown
- 2016-12-09 PE PE2023001148A patent/PE20240817A1/es unknown
- 2016-12-09 EP EP16816405.1A patent/EP3393512A1/en active Pending
- 2016-12-09 CN CN201680075615.8A patent/CN108738312A/zh active Pending
- 2016-12-09 IL IL260203A patent/IL260203B1/en unknown
- 2016-12-09 KR KR1020207020668A patent/KR102505354B1/ko active IP Right Grant
- 2016-12-09 BR BR112018010805-7A patent/BR112018010805A2/pt active Search and Examination
- 2016-12-09 PE PE2018001128A patent/PE20181354A1/es unknown
- 2016-12-09 JP JP2018532448A patent/JP6817307B2/ja active Active
- 2016-12-09 PE PE2023001147A patent/PE20232039A1/es unknown
- 2016-12-09 SG SG11201804148TA patent/SG11201804148TA/en unknown
- 2016-12-09 IL IL311990A patent/IL311990A/en unknown
- 2016-12-19 CA CA2952131A patent/CA2952131C/en active Active
- 2016-12-19 CA CA3217696A patent/CA3217696A1/en active Pending
- 2016-12-20 US US15/385,611 patent/US9950058B2/en active Active
- 2016-12-22 TW TW107131547A patent/TWI707866B/zh active
- 2016-12-22 TW TW105142706A patent/TWI656130B/zh active
- 2016-12-22 TW TW109132170A patent/TWI756828B/zh active
- 2016-12-22 TW TW111102562A patent/TWI838685B/zh active
-
2018
- 2018-02-14 US US15/896,871 patent/US10238732B2/en active Active
- 2018-06-18 CO CONC2018/0006301A patent/CO2018006301A2/es unknown
- 2018-06-20 SA SA522433260A patent/SA522433260B1/ar unknown
- 2018-06-20 SA SA518391839A patent/SA518391839B1/ar unknown
- 2018-06-20 MX MX2021007070A patent/MX2021007070A/es unknown
- 2018-06-22 PH PH12018501355A patent/PH12018501355A1/en unknown
-
2019
- 2019-01-08 US US16/242,799 patent/US10821171B2/en active Active
- 2019-07-31 AU AU2019210579A patent/AU2019210579B2/en active Active
-
2020
- 2020-10-01 US US17/060,944 patent/US20210023200A1/en not_active Abandoned
- 2020-12-24 JP JP2020214835A patent/JP7193522B2/ja active Active
-
2021
- 2021-04-23 AU AU2021202522A patent/AU2021202522C1/en active Active
-
2022
- 2022-09-28 JP JP2022154365A patent/JP7212198B2/ja active Active
- 2022-11-17 JP JP2022184277A patent/JP2023015335A/ja active Pending
-
2023
- 2023-03-29 US US18/192,352 patent/US20230218738A1/en active Pending
- 2023-08-09 AU AU2023214269A patent/AU2023214269A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181354A1 (es) | Mutantes de proteina f de rsv | |
CY1123642T1 (el) | Αντισωματα enanti-pd-1 | |
CY1124806T1 (el) | Αντισωματα enanti-cd40 και χρησεις αυτων | |
EA201892250A1 (ru) | Вакцина против rsv | |
CY1123274T1 (el) | Αντισωματα εναντι-οχ40 και χρησεις αυτων | |
EA201990071A1 (ru) | Композиция пептидной вакцины | |
MD3827845T2 (ro) | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora | |
CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
EA201892251A1 (ru) | Стабилизированные растворимые f-белки rsv до слияния | |
EA201892202A1 (ru) | Способы лечения холестатических заболеваний | |
BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
AR108920A1 (es) | Partículas y composiciones de nicotina | |
WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
PE20181176A1 (es) | Composiciones biofarmaceuticas | |
WO2015107363A3 (en) | Mycobacterial antigen composition | |
CY1125143T1 (el) | Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων | |
EA201791957A1 (ru) | Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов | |
MY179251A (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
EA201990998A1 (ru) | Фармацевтические составы и способы их получения | |
NZ774126A (en) | Spd-1 variant - fc fusion proteins | |
BR112017007370A2 (pt) | "conjunto separador de pedra para uma colheitadeira" | |
CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. |